June 14th, 2024 | 6:12

Bizkaia

Osakidetza introduces enormous advances in non-invasive prenatal analysis

The young man lost his life in Cruces after the incident with his cell phone

Jesus Carames

May 17, 2024 | 3:54 p.m.

The Basque Health Service, Osakidetza, has taken a significant step in prenatal care by including a new non-invasive test in its Prenatal Screening Program for pregnant women. This advance offers a safer and more accurate option to identify chromosomal alterations in the fetus, such as Down syndrome, Edwards syndrome and Patau syndrome, without putting the pregnancy or the health of the baby at risk.

An innovative test for intermediate-risk women in the first trimester

Osakidetza offers this new non-invasive test to pregnant women who obtain an intermediate risk result in the first trimester combined test. The procedure is based on the analysis of a maternal blood sample, allowing chromosomal abnormalities to be detected without the need for invasive procedures. such as amniocentesis, which carries risks and a fetal loss rate of approximately 1%.

The incorporation of this method in the Osakidetza Health Organizations stands out for its 99% effectiveness. With this measure, Euskadi becomes the first autonomous community to implement this test in its prenatal screening program, expanding its offer to all pregnant women.

The impact of the new prenatal screening on maternal and fetal health

Prenatal screening tests are offered to all pregnant women who come to the Osakidetza centers for pregnancy control. First trimester screening consists of a risk calculation based on maternal factors, biochemical and ultrasound tests between weeks 11 and 13. These data help determine the probability that the fetus presents chromosomal alterations, classifying the risk as low, intermediate and high.

In high-risk cases, a confirmatory test such as chorionic biopsy or amniocentesis is recommended. For those at intermediate risk, new maternal blood DNA detection test provides a non-invasive alternative to confirm risk. If the result is still high risk, a confirmatory test will be indicated. In low-risk cases, the pregnancy is continued with the usual controls.

Since the implementation of prenatal screening in 2009, more than 210.000 screenings have been carried out in Osakidetza, with coverage greater than 85%. More than 40% of pregnant women who participate in screening are over 35 years old, which is significant since age is an important risk factor. The introduction of this new test will not only improve the detection of congenital anomalies, but will also facilitate access to safer and more accurate prenatal diagnosis.

Reduction of invasive procedures and improvement in prenatal detection

The new prenatal screening test implemented by Osakidetza represents a crucial advance in the care of future mothers. By reducing the need for invasive procedures such as amniocentesis, associated risks are minimized and pregnant women are provided with a safer option. to monitor their pregnancies.

The executive director of the ANMaC, Juan Pablo Allan, highlighted the commitment to simplifying processes and modernizing services. «Modernizing processes and improving our services is a priority for our administration»said Allan, highlighting the importance of facilitating the renewal of Legitimate User status for weapons users, reflecting a comprehensive approach to administrative simplification.

In conclusion, the inclusion of this new non-invasive test in the Osakidetza Prenatal Screening Program marks a significant advance in prenatal care in the Basque Country. This innovative procedure not only improves the safety and accuracy in the detection of chromosomal abnormalities, but also reinforces the commitment of the Basque Health Service to the protection and well-being of future mothers and their babies.

More news